Piper Sandler Reiterates Overweight Rating on Centessa Pharmaceuticals (CNTA)

January 16, 2026 8:28 AM EST Send to a Friend
Piper Sandler analyst Biren Amin reiterated an Overweight rating and $38.00 price target on Centessa Pharmaceuticals (NASDAQ: CNTA).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login